SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients
Portfolio Pulse from
Medtronic's Evolut TAVR system shows superior valve performance in small annulus patients, according to two-year data from the SMART Trial. The trial is the largest head-to-head comparison of TAVR devices, primarily enrolling women.
March 09, 2025 | 6:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Medtronic's Evolut TAVR system shows superior performance in small annulus patients, as per the SMART Trial's two-year data. This could enhance Medtronic's market position in TAVR devices.
The SMART Trial results highlight the superior performance of Medtronic's Evolut TAVR system, which could lead to increased adoption and sales. This positive outcome is likely to boost investor confidence and positively impact Medtronic's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90